Copyright Reports & Markets. All rights reserved.

Global and China Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Hyaluronic Acid
    • 1.2.3 Collagen
    • 1.2.4 Polyethylene glycol (PEG)
    • 1.2.5 polylactic-co-glycolic acid (PGLA)
    • 1.2.6 Others
  • 1.3 Market by Application
    • 1.3.1 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Share by Application: 2020 VS 2026
    • 1.3.2 Knee Cartilage Repair
    • 1.3.3 Hip Cartilage Repair
    • 1.3.4 Elbow Cartilage Repair
    • 1.3.5 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Perspective (2015-2026)
  • 2.2 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Growth Trends by Regions
    • 2.2.1 Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Autologous Matrix-Induced Chondrogenesis (AMIC) Historic Market Share by Regions (2015-2020)
    • 2.2.3 Autologous Matrix-Induced Chondrogenesis (AMIC) Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Autologous Matrix-Induced Chondrogenesis (AMIC) Players by Market Size
    • 3.1.1 Global Top Autologous Matrix-Induced Chondrogenesis (AMIC) Players by Revenue (2015-2020)
    • 3.1.2 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue Market Share by Players (2015-2020)
  • 3.2 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue
  • 3.4 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Concentration Ratio
    • 3.4.1 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Autologous Matrix-Induced Chondrogenesis (AMIC) Revenue in 2019
  • 3.5 Key Players Autologous Matrix-Induced Chondrogenesis (AMIC) Area Served
  • 3.6 Key Players Autologous Matrix-Induced Chondrogenesis (AMIC) Product Solution and Service
  • 3.7 Date of Enter into Autologous Matrix-Induced Chondrogenesis (AMIC) Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Autologous Matrix-Induced Chondrogenesis (AMIC) Breakdown Data by Type (2015-2026)

  • 4.1 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Historic Market Size by Type (2015-2020)
  • 4.2 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Forecasted Market Size by Type (2021-2026)

5 Autologous Matrix-Induced Chondrogenesis (AMIC) Breakdown Data by Application (2015-2026)

  • 5.1 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Historic Market Size by Application (2015-2020)
  • 5.2 Global Autologous Matrix-Induced Chondrogenesis (AMIC) Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size (2015-2026)
  • 6.2 North America Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Type (2015-2020)
  • 6.3 North America Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Application (2015-2020)
  • 6.4 North America Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size (2015-2026)
  • 7.2 Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Type (2015-2020)
  • 7.3 Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Application (2015-2020)
  • 7.4 Europe Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size (2015-2026)
  • 8.2 China Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Type (2015-2020)
  • 8.3 China Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Application (2015-2020)
  • 8.4 China Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size (2015-2026)
  • 9.2 Japan Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Type (2015-2020)
  • 9.3 Japan Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Application (2015-2020)
  • 9.4 Japan Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size (2015-2026)
  • 10.2 Southeast Asia Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Autologous Matrix-Induced Chondrogenesis (AMIC) Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Anika Therapeutics, Inc.
    • 11.1.1 Anika Therapeutics, Inc. Company Details
    • 11.1.2 Anika Therapeutics, Inc. Business Overview
    • 11.1.3 Anika Therapeutics, Inc. Autologous Matrix-Induced Chondrogenesis (AMIC) Introduction
    • 11.1.4 Anika Therapeutics, Inc. Revenue in Autologous Matrix-Induced Chondrogenesis (AMIC) Business (2015-2020))
    • 11.1.5 Anika Therapeutics, Inc. Recent Development
  • 11.2 Arthro-Kinetics
    • 11.2.1 Arthro-Kinetics Company Details
    • 11.2.2 Arthro-Kinetics Business Overview
    • 11.2.3 Arthro-Kinetics Autologous Matrix-Induced Chondrogenesis (AMIC) Introduction
    • 11.2.4 Arthro-Kinetics Revenue in Autologous Matrix-Induced Chondrogenesis (AMIC) Business (2015-2020)
    • 11.2.5 Arthro-Kinetics Recent Development
  • 11.3 B. Braun Melsungen AG
    • 11.3.1 B. Braun Melsungen AG Company Details
    • 11.3.2 B. Braun Melsungen AG Business Overview
    • 11.3.3 B. Braun Melsungen AG Autologous Matrix-Induced Chondrogenesis (AMIC) Introduction
    • 11.3.4 B. Braun Melsungen AG Revenue in Autologous Matrix-Induced Chondrogenesis (AMIC) Business (2015-2020)
    • 11.3.5 B. Braun Melsungen AG Recent Development
  • 11.4 BioTissue AG
    • 11.4.1 BioTissue AG Company Details
    • 11.4.2 BioTissue AG Business Overview
    • 11.4.3 BioTissue AG Autologous Matrix-Induced Chondrogenesis (AMIC) Introduction
    • 11.4.4 BioTissue AG Revenue in Autologous Matrix-Induced Chondrogenesis (AMIC) Business (2015-2020)
    • 11.4.5 BioTissue AG Recent Development
  • 11.5 CartiHeal
    • 11.5.1 CartiHeal Company Details
    • 11.5.2 CartiHeal Business Overview
    • 11.5.3 CartiHeal Autologous Matrix-Induced Chondrogenesis (AMIC) Introduction
    • 11.5.4 CartiHeal Revenue in Autologous Matrix-Induced Chondrogenesis (AMIC) Business (2015-2020)
    • 11.5.5 CartiHeal Recent Development
  • 11.6 Geistlich Pharma AG
    • 11.6.1 Geistlich Pharma AG Company Details
    • 11.6.2 Geistlich Pharma AG Business Overview
    • 11.6.3 Geistlich Pharma AG Autologous Matrix-Induced Chondrogenesis (AMIC) Introduction
    • 11.6.4 Geistlich Pharma AG Revenue in Autologous Matrix-Induced Chondrogenesis (AMIC) Business (2015-2020)
    • 11.6.5 Geistlich Pharma AG Recent Development
  • 11.7 JRI Orthopaedics Ltd.
    • 11.7.1 JRI Orthopaedics Ltd. Company Details
    • 11.7.2 JRI Orthopaedics Ltd. Business Overview
    • 11.7.3 JRI Orthopaedics Ltd. Autologous Matrix-Induced Chondrogenesis (AMIC) Introduction
    • 11.7.4 JRI Orthopaedics Ltd. Revenue in Autologous Matrix-Induced Chondrogenesis (AMIC) Business (2015-2020)
    • 11.7.5 JRI Orthopaedics Ltd. Recent Development
  • 11.8 Matricel GmbH
    • 11.8.1 Matricel GmbH Company Details
    • 11.8.2 Matricel GmbH Business Overview
    • 11.8.3 Matricel GmbH Autologous Matrix-Induced Chondrogenesis (AMIC) Introduction
    • 11.8.4 Matricel GmbH Revenue in Autologous Matrix-Induced Chondrogenesis (AMIC) Business (2015-2020)
    • 11.8.5 Matricel GmbH Recent Development
  • 11.9 Smith & Nephew plc
    • 11.9.1 Smith & Nephew plc Company Details
    • 11.9.2 Smith & Nephew plc Business Overview
    • 11.9.3 Smith & Nephew plc Autologous Matrix-Induced Chondrogenesis (AMIC) Introduction
    • 11.9.4 Smith & Nephew plc Revenue in Autologous Matrix-Induced Chondrogenesis (AMIC) Business (2015-2020)
    • 11.9.5 Smith & Nephew plc Recent Development
  • 11.10 Zimmer Biomet Holdings
    • 11.10.1 Zimmer Biomet Holdings Company Details
    • 11.10.2 Zimmer Biomet Holdings Business Overview
    • 11.10.3 Zimmer Biomet Holdings Autologous Matrix-Induced Chondrogenesis (AMIC) Introduction
    • 11.10.4 Zimmer Biomet Holdings Revenue in Autologous Matrix-Induced Chondrogenesis (AMIC) Business (2015-2020)
    • 11.10.5 Zimmer Biomet Holdings Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Autologous Matrix-Induced Chondrogenesis (AMIC) Scope and Market Size
    Autologous Matrix-Induced Chondrogenesis (AMIC) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Autologous Matrix-Induced Chondrogenesis (AMIC) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Hyaluronic Acid
    Collagen
    Polyethylene glycol (PEG)
    polylactic-co-glycolic acid (PGLA)
    Others

    Market segment by Application, split into
    Knee Cartilage Repair
    Hip Cartilage Repair
    Elbow Cartilage Repair
    Others

    Based on regional and country-level analysis, the Autologous Matrix-Induced Chondrogenesis (AMIC) market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Autologous Matrix-Induced Chondrogenesis (AMIC) market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Anika Therapeutics, Inc.
    Arthro-Kinetics
    B. Braun Melsungen AG
    BioTissue AG
    CartiHeal
    Geistlich Pharma AG
    JRI Orthopaedics Ltd.
    Matricel GmbH
    Smith & Nephew plc
    Zimmer Biomet Holdings

    Buy now